The prescription is ready. You keep looking at it. What if you feel numb? Gain weight? Need it forever? You may want relief and still feel afraid of psychiatric medication. Bring that fear into the visit. It belongs in the decision, along with your symptoms, health history, and goals.
What should you know before taking psychiatric medication?
Before taking psychiatric medication, ask which symptoms the drug should help, what benefits and side effects to track, when you will review the plan, and how your prescriber would help you stop safely if needed, because the risks and benefits depend on the medicine and your health.1
Fear 1: “What if I get hooked?”
What this fear gets right: Some medicines can cause withdrawal when they are reduced or stopped. That can happen even when someone used them exactly as prescribed.15
The body can get used to a drug. When the drug is reduced or stopped, withdrawal symptoms can follow. The FDA calls this physical dependence in its benzodiazepine warning.5 For antidepressants, NICE uses the plainer term withdrawal symptoms.1 Addiction is a different problem. It means compulsive drug seeking and use despite harm.21 Withdrawal alone does not establish addiction. Antidepressant withdrawal still needs care. The label for sertraline, a common antidepressant, says it is not a controlled substance and showed no sign of abuse potential in testing.20
Why do antidepressant withdrawal estimates differ?
A large 2024 review found at least one symptom in about 31% of people stopping an antidepressant and 17% stopping a placebo. Its authors estimated that about 15% had symptoms attributable to stopping the drug after accounting for background symptoms. Severe symptoms were reported in about 3% of people stopping an antidepressant, compared with under 1% of people stopping a placebo. These are group estimates with wide differences between studies.2
A 2025 review found about one extra symptom, on average, one week after stopping, compared with people who stayed on an antidepressant or were in placebo groups. An older review reported much higher rates. The studies differed in whom they included, how they asked about symptoms, and how long they watched. An early average cannot tell us how often long, difficult withdrawal occurs after years of treatment. No single number settles every person’s risk.34
This disagreement supports a careful plan. It does not support dismissing symptoms or assuming that everyone will have severe withdrawal.
Benzodiazepines and stimulants need their own discussion
Benzodiazepines include medicines such as alprazolam and lorazepam. The FDA warns about dependence, misuse, and addiction. Dependence can develop within days to weeks of regular use. Abrupt stopping can cause dangerous withdrawal, including seizures. Alcohol and opioids can add serious risk.5
Prescription stimulants, used for ADHD and other conditions, also carry warnings about misuse, addiction, and overdose. Those warnings deserve attention. They do not mean a person taking a prescribed stimulant is automatically addicted. The plan should include safe use, secure storage, and ongoing review. Never share a prescription.6
Ask: “Does this drug cause withdrawal? What is my risk of addiction? Who will help me if I miss doses or someday want to stop?”
For the full stopping discussion, read tapering and antidepressant withdrawal. A taper means gradual changes planned with a clinician. The pace depends on the medicine and your response; there is no single schedule for everyone.15
Fear 2: “Will I stop being myself?”
What this fear gets right: Emotional blunting can happen. People may describe less joy, less sadness, or a sense that they cannot care as deeply. Depression itself can also leave people numb, which makes the cause hard to sort out.7
Think of a dimmer switch turned too low. Both pleasant and painful feelings seem less bright. That describes an experience, not proof that a medicine caused it.
Surveys of people taking certain antidepressants have found substantial reports of blunting. Those surveys cannot tell us how many new cases a drug causes. People with more remaining depression symptoms also tend to report more blunting. Dose may play a part, but strong trials of how best to manage it are limited.7
“Medication never changes personality” is too broad a promise. In one trial, people taking paroxetine had changes in measured traits, including less tendency toward distress and more outward engagement. A score on a trait scale does not tell us whether someone feels like themselves, and one drug trial cannot predict your experience.8
The useful question is what changed for you. Can you enjoy a song again? Do you feel less trapped by worry? Or have you stopped caring about things you value? Bring examples from before and after treatment.
Ask: “Could this flat feeling be a side effect, depression that remains, or both? What options would you consider?”
A clinician may consider a dose change or another treatment after reviewing the cause. These are shared decisions, not changes to make yourself. You deserve more than being told to accept numbness because you cry less.7 Read more about depression and feeling flat. If you are still weighing your options, see therapy, medication, or both.
Fear 3: “Will I gain weight?”
What this fear gets right: Weight effects vary by medicine. A change that matters to you deserves attention, even if a study calls the average change small.
A large 2024 study compared eight common antidepressants. Bupropion was linked to less weight gain than sertraline. Escitalopram, paroxetine, and duloxetine were linked to somewhat more at six months. Compared with sertraline, each average difference was under half a kilogram, or about one pound. This was a study of health records, not random assignment. Many people did not stay on the first drug, so the results guide a discussion rather than predict a person’s weight.9
Among antipsychotic drugs, trials in people with schizophrenia found higher metabolic risks with olanzapine and clozapine. Aripiprazole, lurasidone, and ziprasidone had lower risks in that comparison. Lower risk does not mean no risk. Those findings also cannot choose the right treatment for another condition by themselves.10
Mirtazapine can increase appetite and weight. That effect may be unwanted, or it may fit a person’s needs when poor appetite is part of depression. The choice still depends on the whole health picture.11
Ask: “Which options fit my symptoms and have less weight risk? What will we measure, and when will we act on a change?”
Ask about a starting weight and any needed blood sugar or cholesterol checks. These checks are especially relevant with some antipsychotic medicines.15 If seeing the scale is distressing, say so. You can ask the care team how to track health without making each visit feel like a judgment.
Do not turn a drug ranking into your own prescription. Tell the clinician about past weight changes, eating concerns, sleep, and what you most want to avoid.
Fear 4: “Once I start, is it forever?”
What this fear gets right: Some people benefit from long-term treatment. Feeling better does not always mean the risk of another episode has passed.11
For major depression, CANMAT recommends continuing an effective antidepressant for six to twelve months after remission, meaning symptoms have largely cleared. People with repeated episodes or other relapse risks may need two years or longer. The clock is not simply six months from the first pill.11
Other conditions have different plans. NICE recommends at least a year of effective drug treatment for generalized anxiety disorder. For adult OCD, it recommends at least twelve months of effective SSRI treatment, with a review after twelve months in remission.1617
Bipolar disorder and psychotic disorders may need ongoing relapse prevention. NICE advises discussing long-term treatment in bipolar disorder and warns of high relapse risk when antipsychotics are stopped in the first one to two years after a psychotic episode. That warning is not a universal date to stop.1819
Ask: “What would tell us I am ready to discuss stopping? What makes a longer course sensible for me? When will we revisit this?”
Put a review date in the plan. A review can lead to continuing treatment, changing it, or planning a supervised taper. It should include your goals and any burden from treatment. For more detail, see how long to stay on an antidepressant. For the early weeks, see the 90-day treatment timeline.
Fear 5: “What will taking this say about me?”
What this fear gets right: Stigma exists. People may face unfair ideas about mental illness, then start applying those ideas to themselves. Shame can make it harder to seek support.13
You may hear, “You should be able to handle this,” from someone you love. You may also say it to yourself. At the visit, try turning that sentence into a question: “What are the likely costs of treating this, and what are the likely costs of leaving it untreated?”
Work questions deserve precise answers. In most situations, you can keep a mental health condition private from an employer. There are exceptions, including some requests for workplace changes and certain questions about ability to work safely. The EEOC explains these limits and protections.12
A professional license, safety-sensitive job, or security process may have separate rules. This essay cannot promise the same answer for every job. Bring the actual form or question to a qualified adviser. Do not rely on a blanket claim that treatment always harms a career or can never affect a work decision.
Ask: “Who can see my treatment information? Which parts of my concern are about medical risk, and which are about what other people might think?”
If you need a clinician who will make room for these questions, start with choosing a psychiatric provider.
Two concerns to name out loud
Sexual side effects belong in the conversation. Some antidepressants can affect desire, arousal, or orgasm. Ask what to track and what options exist if a change troubles you. You do not need to wait until the clinician asks.1520
The FDA boxed warning about antidepressants concerns increased suicidal thoughts and behavior in children, teens, and young adults in short-term studies. Adults under 25 need particular attention early in treatment and after dose changes. In the same pooled studies, the label reports no increase in adults 25 to 64 and fewer cases in adults 65 and older. People of all ages still need monitoring. The warning is a reason for a clear safety plan, not a prediction that this will happen to you.1520
Fear can also shape how symptoms are noticed and experienced. This is part of the nocebo effect. It does not mean a symptom is invented. A useful consent discussion explains common effects, serious warning signs, and what help is available, without hiding risk or treating every sensation as danger.14
Save this medication conversation card
Fill in the first column before your visit. Ask the clinician to help complete the second. These are prompts, not a test of whether you are ready for treatment.
| Bring this concern | Leave with this answer |
|---|---|
| The symptom I most want help with: ___ | What improvement would look like: ___ |
| The side effect I most fear: ___ | Its risk with this drug and our backup plan: ___ |
| A past drug reaction or stopping problem: ___ | How it changes this plan: ___ |
| My worry about weight, sex, or feeling flat: ___ | What we will track: ___ |
| My question about staying on treatment: ___ | When we will review the need: ___ |
| The best way to reach me: ___ | Who to contact between visits: ___ |
You can begin with one sentence: “I want help, and I need us to talk about what scares me before we decide.” For the rest of the history to share, see what to tell your psychiatrist at the first visit. If you are still weighing whether to seek care, read when to ask for psychiatric help.
When to get help now
New suicidal thoughts, sharply worse mood, or severe agitation need prompt clinical help. Trouble breathing, collapse, or a severe reaction needs emergency evaluation. Do not wait for the next routine visit or manage a serious reaction with your own dose changes.51520
Use the urgent mental health care guide to choose the next step.
Key takeaways
- The name of the medicine matters. Risks differ across drugs.1
- Withdrawal and addiction describe different problems.521
- Feeling flat or having sexual side effects deserves a clear discussion.715
- A treatment plan should include follow-up and a future review.11
- You do not have to hide your fear to be a good patient.
Frequently asked questions
Are antidepressants addictive?
They can cause withdrawal symptoms when you cut down or stop.1 That is different from addiction, which means compulsive drug seeking and use despite harm.21 Stopping still needs a plan with your prescriber.1
Will an antidepressant change my personality?
Some people report unwanted emotional blunting; others notice changes as depression improves. Research on personality traits cannot predict how you will feel. Tell the prescriber what feels better and what feels unlike you.78
Which antidepressant is least likely to cause weight gain?
Bupropion had the least weight gain in one large comparison of eight common drugs. That does not make it the best or safest choice for every person. Your clinician should consider your symptoms and health history.9
Can I stop once I feel better?
Discuss that wish with your prescriber. Feeling better may be a reason to continue relapse prevention for a time. Do not stop abruptly or build your own taper; ask for a plan and follow-up.111
Related reading on NP FADY
- How Long Until Treatment Works? A 90-Day Timeline
- What to Tell Your Psychiatrist at the First Visit
- Therapy, Medication, or Both?
- Choosing a psychiatric provider
References
1. NICE. Depression in adults: treatment and management. NICE guideline NG222. Recommendations.
2. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526-535. doi:10.1016/S2215-0366(24)00133-0. A correction was published (PMID 39096930).
3. Kalfas M, Tsapekos D, Butler M, et al. Incidence and nature of antidepressant discontinuation symptoms: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82(9):896-904. doi:10.1001/jamapsychiatry.2025.1362.
4. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav. 2019;97:111-121. doi:10.1016/j.addbeh.2018.08.027.
5. FDA. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Drug Safety Communication, September 23, 2020. Verified September 18, 2026.
6. FDA. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Drug Safety Communication, May 11, 2023. Verified September 18, 2026.
7. Ma H, Cai M, Wang H. Emotional blunting in patients with major depressive disorder: a brief non-systematic review of current research. Front Psychiatry. 2021;12:792960. doi:10.3389/fpsyt.2021.792960.
8. Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Schalet B. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry. 2009;66(12):1322-1330. doi:10.1001/archgenpsychiatry.2009.166.
9. Petimar J, Young JG, Yu H, et al. Medication-induced weight change across common antidepressant treatments: a target trial emulation study. Ann Intern Med. 2024;177(8):993-1003. doi:10.7326/M23-2742. PMID 38950403.
10. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77. doi:10.1016/S2215-0366(19)30416-X.
11. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641-687. doi:10.1177/07067437241245384.
12. EEOC. Depression, PTSD, and other mental health conditions in the workplace: your legal rights. EEOC-NVTA-2016-11, issued December 12, 2016. Verified September 18, 2026.
13. American Psychiatric Association. Stigma, prejudice and discrimination against people with mental illness.
14. Burke MJ, Sandra DA, Peciña M, et al. Harnessing placebo effects and mitigating nocebo effects: implications for clinical practice in psychiatry and medicine. Lancet Psychiatry. 2026;13(5):413-425. doi:10.1016/S2215-0366(25)00340-2.
15. NIMH. Mental health medications.
16. NICE. Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline CG113.
17. NICE. Obsessive-compulsive disorder and body dysmorphic disorder: treatment. Clinical guideline CG31.
18. NICE. Bipolar disorder: assessment and management. Clinical guideline CG185.
19. NICE. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178.
20. ZOLOFT (sertraline hydrochloride) prescribing information, revised August 2023. FDA-approved labeling on DailyMed: boxed warning and sections 5.1, 5.5, 5.11, and 9. Verified September 18, 2026.
21. National Institute on Drug Abuse. Drugs, Brains, and Behavior: The Science of Addiction. Drug misuse and addiction. Verified September 18, 2026.
This article is for education and is not a substitute for care from a qualified health professional. Do not start, stop, or change medication without your prescriber’s guidance. Evidence last checked September 18, 2026.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.